Abstract
The introduction of tumor necrosis factor (TNF) inhibitors in the late 1990s significantly changed the therapeutic approach for rheumatoid arthritis (RA). With the approval of subsequent TNF inhibitors as well as other biologic agents effective in the management of RA, the treatment paradigm has become increasingly complex. This review examines the current literature regarding the efficacy and toxicity of these and other new anti-rheumatic therapies and discusses effective therapeutic strategies for their use.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 35-43 |
| Number of pages | 9 |
| Journal | Open Access Rheumatology: Research and Reviews |
| Volume | 2 |
| DOIs | |
| State | Published - 2010 |
Keywords
- Abatacept
- Adalimumab
- Biologics
- Certolizumab
- Dmards
- Etancercept
- Golimumab
- Infliximab
- Rituximab
- Tocilizumab
- Tumor necrosis factor inhibitors
ASJC Scopus subject areas
- Rheumatology